News
Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback